Outcome
    Moderate Evidence

    Huperzine A for Neuroprotection

    Neuroprotective effects beyond symptomatic cholinergic action are unproven in humans.

    Overview

    Neuroprotective effects beyond symptomatic cholinergic action are unproven in humans.

    Verdict

    Insufficient evidence

    How It Works

    Huperzine A shows NMDA receptor antagonism and anti-apoptotic effects in preclinical models independent of cholinesterase inhibition.

    Dosing & Protocol

    Typical dose

    Recommended dose
    Not established; neuroprotection is demonstrated only in animal models, with no human trial measuring neuroprotective outcomes
    Expected timeframe
    Not established

    Protocol

    form
    Not applicable
    duration
    Not applicable
    co factor
    Evidence is insufficient. In animal models huperzine A reduces neuronal damage from glutamate excitotoxicity, beta-amyloid and ischaemia, apparently through NMDA receptor antagonism and mitochondrial effects independent of its cholinesterase activity, and it has been investigated as a protective agent against organophosphate nerve agents. None of this has been tested in humans as a neuroprotective endpoint: the human trials measured cognitive scores in Alzheimer disease, not neuronal survival, brain volume or disease progression, and a US trial in mild to moderate Alzheimer disease failed to show benefit at 200 mcg twice daily. Symptomatic cholinergic effect and neuroprotection are different claims, and only the former has any human data.
    titration
    Not applicable
    starting dose
    Not applicable as an established treatment

    Evidence

    What the studies say

    Animal models suggest reduced excitotoxic and ischaemic damage. A US trial in Alzheimer disease found no disease-modifying benefit at the primary endpoint.

    No studies are yet linked to both Huperzine A and Neuroprotection.

    Safety

    Caveats

    Neurological symptoms need medical assessment - sudden weakness, speech difficulty or facial droop is a stroke needing emergency care, and progressive symptoms need neurology input while treatable causes can still be found. Safety ceiling: huperzine A is a potent cholinesterase inhibitor, not a benign botanical - do not exceed 400 mcg/day and never combine it with donepezil, rivastigmine or galantamine, since additive cholinergic effects can cause bradycardia, seizures, bronchospasm and cholinergic crisis. Avoid with beta-blockers, anticholinergics and neuromuscular blockers; stop two weeks before surgery and tell your anaesthetist. Contraindicated in epilepsy - which matters because seizure risk cuts directly against a neuroprotective claim - and in asthma or COPD, peptic ulcer disease, bradycardia or heart block, and urinary obstruction. No safety data in pregnancy or breastfeeding - avoid in both, and in children. Long-term safety is unestablished.

    Less likely to help if

    Everyone: no human neuroprotective outcome data exist.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.